Bumper Offer - Urjas oil Just @ Rs. 1
Levolin 1.25 Mg Respule is a prescription medicine that is available as a Respules. It is primarily used for the treatment of Asthma. Other than this, Levolin 1.25 Mg Respule has some other therapeutic uses, which have been discussed ahead.
The right dosage of Levolin 1.25 Mg Respule depends on the age, gender, and medical history of the patient. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. Detailed information has been provided in the dosage section.
Apart from the aforementioned side effects, Levolin 1.25 Mg Respule can also lead to other problems, which have been listed below. Such side effects of Levolin 1.25 Mg Respule normally do not last long and go away once the treatment is completed. Please speak with your doctor if these side effects worsen or persist for a longer duration.
In addition, Levolin 1.25 Mg Respule's effect is Moderate during pregnancy and Moderate for lactating mothers. It is important to know if Levolin 1.25 Mg Respule has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Levolin 1.25 Mg Respule related warnings section.
The section on Levolin 1.25 Mg Respule contraindications lists all such conditions.
Drug reaction of Levolin 1.25 Mg Respule with other medicines has been reported. Refer to the list below for further details.
In addition to these precautions, you may also note that Levolin 1.25 Mg Respule is not safe while driving, and is is not addictive in nature.
Levolin 1.25 Mg Respule is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| 13 - 18 years (Adolescent) |
|
| 2 - 12 years (Child) |
|
| Adult |
|
| Geriatric |
|
Is the use of Levolin 1.25 Mg Respule safe for pregnant women?
Levolin can have harmful effects in pregnant women. If you experience any discomfort after using Levolin, then discontinue the use and take your doctor's advice.
Is the use of Levolin 1.25 Mg Respule safe during breastfeeding?
Levolin can cause moderate side effects on breastfeeding women. If you feel its side effects, then stop taking this drug and consult your doctor. Take this medicine again only if your doctor advises to do so.
What is the effect of Levolin 1.25 Mg Respule on the Kidneys?
Levolin rarely harms the kidneys.
What is the effect of Levolin 1.25 Mg Respule on the Liver?
Levolin does not damage the liver.
What is the effect of Levolin 1.25 Mg Respule on the Heart?
Levolin has very mild side effects on the heart.
Levolin 1.25 Mg Respule should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Levolin 1.25 Mg Respule unless your doctor advises you to do so -
Is this Levolin 1.25 Mg Respule habit forming or addictive?
Levolin 1.25 Mg Respule does not cause addiction.
Is it safe to drive or operate heavy machinery when consuming?
You may feel sleepy or tired after taking Levolin 1.25 Mg Respule. So it is best to avoid driving.
Is it safe?
Yes, but take Levolin 1.25 Mg Respule only as per medical advice.
Is it able to treat mental disorders?
There is no benefit of taking Levolin 1.25 Mg Respule for mental disorders.
Interaction between Food and Levolin 1.25 Mg Respule
It is safe to take Levolin 1.25 Mg Respule with food.
Interaction between Alcohol and Levolin 1.25 Mg Respule
Consult your doctor before consuming alcohol while taking Levolin 1.25 Mg Respule as it can have severe side effects.
This medicine data has been created by -
B.Pharma, Pharmacy
7 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Xopenex® (levalbuterol hydrochloride)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 763-765
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Xopenex® (levalbuterol hydrochloride)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 763-765
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Xopenex® (levalbuterol hydrochloride)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 763-765
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Xopenex® (levalbuterol hydrochloride)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 763-765
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Xopenex® (levalbuterol hydrochloride)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 763-765
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Xopenex® (levalbuterol hydrochloride)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 763-765
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Xopenex® (levalbuterol hydrochloride)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 763-765
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Xopenex® (levalbuterol hydrochloride)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 763-765
